

**Farxiga (dapagliflozin)**  
**Prior Authorization Request Form**  
Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

**MEMBER'S LAST NAME:** \_\_\_\_\_ **MEMBER'S FIRST NAME:** \_\_\_\_\_

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION		
LAST NAME:		FIRST NAME:
PHONE NUMBER:		DATE OF BIRTH:
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

☐ MALE ☐ FEMALE HEIGHT (IN/CM): \_\_\_\_\_ WEIGHT (LB/KG): \_\_\_\_\_ ALLERGIES: \_\_\_\_\_

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [PRIMETHERAPEUTICS.COM/NOPP](https://www.primetherapeutics.com/nopp)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): \_\_\_\_\_  
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: \_\_\_\_\_

PRESCRIBER INFORMATION	
LAST NAME:	FIRST NAME:
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:
NPI NUMBER:	DEA NUMBER:
PHONE NUMBER:	FAX NUMBER:
STREET ADDRESS:	
CITY:	STATE: ZIP CODE:
REQUESTER (if different than prescriber):	OFFICE CONTACT PERSON:

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

*Continued on next page*

**Farxiga (dapagliflozin)**  
**Prior Authorization Request Form**  
Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

**1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?**

☐ YES (if yes, complete below) ☐ NO

**MEDICATION/THERAPY**  
(SPECIFY DRUG NAME AND  
DOSAGE):

**DURATION OF THERAPY**  
(SPECIFY DATES):

**RESPONSE/REASON FOR  
FAILURE/ALLERGY:**

**2. LIST DIAGNOSES:**

**ICD-10:**

☐ Type II diabetes for blood glucose control

☐ Heart Failure

☐ Type II diabetes with established cardiovascular disease and/or with  
additional cardiovascular risk

☐ Chronic kidney disease

☐ Other diagnosis: \_\_\_\_\_ ICD-10 Code(s):

**3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION  
TO SUPPORT A PRIOR AUTHORIZATION.**

Is patient going to be using drug in a clinical trial? ☐ Yes ☐ No

Patient is required to use the authorized generic dapagliflozin.

Does patient have an absolute contraindication to dapagliflozin? ☐ Yes ☐ No Please submit  
documentation.

For patient with Type II Diabetes only, answer the following:

Is the patient's estimated glomerular filtration rate (GFR) below 25 mL/min/1.73 m<sup>2</sup>?\* ☐ Yes ☐ No

\*Please provide documentation.

Is the patient on dialysis? ☐ Yes ☐ No

Is the patient already taking the requested medication? ☐ Yes ☐ No

Was the patient's hemoglobin A1C (HbA1c) 7.0% or greater prior to therapy (HbA1c must be taken  
within the past 6 months if the patient has not been on this treatment previously)?\* ☐ Yes ☐ No

\*Copy of HbA1c level required.

Is the patient currently on metformin?\* ☐ Yes ☐ No

Does the patient had an inadequate response or intolerance to metformin? ☐ Yes ☐ No

\*Please provide documentation

Does the patient have at least one of the following contraindication to metformin? ☐ Yes ☐ No  
(Please Check one)

**Farxiga (dapagliflozin)**  
**Prior Authorization Request Form**  
Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

☐ Advanced liver disease with cirrhosis, portal hypertension, ascites, and/or hepatic encephalopathy

**For patient with Type II diabetes with established cardiovascular disease and/or risks, answer the following:**

Is the patient 40 years of age or older? ☐ Yes ☐ No

Does patient have Type II diabetes? ☐ Yes ☐ No

Does the patient have established cardiovascular disease as described as ischemic heart disease and/or cerebrovascular disease and/or peripheral arterial disease? ☐ Yes ☐ No *\*Please provide documentation.*

Is the patient a 55 year old(or older) male with dyslipidemia, hypertension and/or who smokes 5 or more cigarettes/day? ☐ Yes ☐ No

Is the patient a 60 year old(or older) female with dyslipidemia, hypertension and/or who smokes 5 or more cigarettes/day? ☐ Yes ☐ No

**For patient with heart failure with or without diabetes, answer the following:**

Has patient ever had NYHA class II, III, or IV symptoms of heart failure? ☐ Yes ☐ No *\*Please provide documentation*

Does patient have ejection fraction of 49% or less? ☐ Yes ☐ No *\*Please provide documentation*

Does patient have ejection fraction of greater than 49% ☐ Yes ☐ No *\*Please provide documentation.*

Does patient's body mass index(BMI) equal less than 50kg/m<sup>2</sup> ? ☐ Yes ☐ No *Please provide documentation.*

Does patient have a NT-proBNP greater than 300pg/ml? ☐ Yes ☐ No *Please provide documentation.*

For patients with A-fib, is the NT-proBNP greater than 600pg/ml? ☐ Yes ☐ No *Please provide documentation.*

If NT-proBNP not available, does patient have a BNP >100pg/ml? ☐ Yes ☐ No *Please submit chart documentation.*

If NT-proBNP not available and patient has Atrial fibrillation (AF), does patient have a BNP >100pg/ml? ☐ Yes ☐ No *Please submit chart documentation*

Does the patient have structural heart disease such as one or more of the following:? ☐ Yes ☐ No *Please provide documentation from echocardiogram.*

☐ LA width >3.8cm

☐ LA length >5.0 cm

☐ LA area >20cm<sup>2</sup>

☐ LA volume >55ml

☐ LA volume index >29ml/m<sup>2</sup>

**Farxiga (dapagliflozin)**  
**Prior Authorization Request Form**  
Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: \_\_\_\_\_ MEMBER'S FIRST NAME: \_\_\_\_\_

Does patient have and eGFR less than 25ml/min/1.73m<sup>2</sup>? ☐ Yes ☐ No

Does patient have severe pulmonary disease including severe COPD, requiring home oxygen therapy for their COPD, chronic nebulizer therapy or chronic oral steroid therapy for treatment of their severe COPD? ☐ Yes ☐ No *Please submit chart documentation.*

Does patient have severe pulmonary disease including WHO group 1 primary pulmonary hypertension? ☐ Yes ☐ No *Please submit chart documentation.*

Does patient have any other condition or diagnosis causing patient's heart failure symptoms such as? ☐ Yes ☐ No *Please submit chart documentation.*

- ☐ Anemia
- ☐ hypothyroidism
- ☐ Known infiltrative cardiomyopathy(e.g. amyloid sarcoid, lymphoma, endomyocardial fibrosis)
- ☐ Active myocarditis
- ☐ Constrictive pericarditis
- ☐ Cardiac tamponade
- ☐ Known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy
- ☐ Arrhythmogenic right ventricular cardiomyopathy/dysplasia
- ☐ Uncorrected primary valvular disease

**For patients with chronic kidney disease with or without diabetes, answer the following:**

Has patient had chronic kidney disease for 3 or more months? ☐ Yes ☐ No *\*Please provide documentation.*

Does patient have and estimated GFR(eGFR) that equals between 20 - 45ml/min/1.73m<sup>2</sup> (inclusive)? ☐ Yes ☐ No *\*Please provide documentation.*

Does patient have and estimated GFR(eGFR) greater than or equal to 45 to less than or equal to 90ml/min/1.73m<sup>2</sup> with urinary albumin:creatinine ratio greater than or equal to 200mg/G or protein:creatinine ratio greater than or equal to 300mg/G? ☐ Yes ☐ No *\*Please provide documentation.*

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

\_\_\_\_\_

\_\_\_\_\_

**Please note:** Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

**ATTESTATION:** I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Farxiga (dapagliflozin)**  
**Prior Authorization Request Form**  
Caterpillar Prescription Drug Benefit  
Phone: 877-228-7909 Fax: 800-424-7640

**MEMBER'S LAST NAME:** \_\_\_\_\_ **MEMBER'S FIRST NAME:** \_\_\_\_\_

**Prescriber Signature or Electronic I.D. Verification:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

**FAX THIS FORM TO:** 800-424-7640  
**MAIL REQUESTS TO:** Prime Therapeutics Management Prior Authorization Program  
Attn: CP-4201  
P.O. Box 64811  
St. Paul, MN 55164-0811  
**Phone:** 877-228-7909